2020

February

Launched Smagen Inc. (registered in USA)

Co-founders:
Prabhat Arya, PhD (Hyderabad/Montreal) Pradip Majumder, PhD (Boston) Michael Green, MD, PhD (UMass Med School, Boston) Gerald Batist, MD (JGH, McGill, Montreal) Rashmi Barbhaiya, PhD (NJ USA)

Smagen Pharmaceuticals aims at transforming the treatment of solid cancer through the use of novel small molecules targeting well-established oncology targets, such as c-Myc, Wnt and other “undruggable” emerging targets either alone or in combination with standard cancer drugs. The company is led by experienced and proven entrepreneurs whose prior oncology and drug development experiences include OICR, BMS, Mitra Biotech, Merck Research Laboratories, McGill Univ, JGH/McGill, Univ of Ottawa, Univ of Massachusetts and Harvard Medical School.

Smagen website is under preparation and will be released shortly: www.smagenpharma.org

2019

February

SignMod and Transcell Oncologics organized one day (February 23, 2019) “Cancer Drug Discovery” meeting with the Hyderabad focus involving speakers from Academia and the pharma sector.

Conference Invitation Conference Snapshot

June

Kudos to the Team!
Filing two US provisional patents related to our Wnt program

Natural Product-Inspired Macrocyclic Compounds as Wnt Transcription Inhibitors. P. Arya, S. Dravida, M. Rao, V. Krishna, A. Kolusu, N. K. Mallurwar. US Provisional Patent, filing date June 14, 2019.

Natural Product-Inspired Compounds as the Inhibitors of Wnt Transcription Machinery. P. Arya, S. Dravida, M. Rao, V. Krishna, A. Kolusu, J. Gaddam. US Provisional Patent, filing date June 25, 2019.